FDA Panel Rejects Lipocine's Testosterone Pill Post author:Sam Post published:January 10, 2018 Post category:BioPharma The FDA voted six in favor and thirteen against the benefit/risk profile of TLANDO. Source: BioSpace You Might Also Like Watch Out! Novartis AG Hungry for Small Takeover Targets With Early-Stage Drugs January 24, 2017 MabVax Therapeutics Board Of Directors Authorizes The Company To Explore Strategic Alternatives July 23, 2017 Why Theranos Could Burn Through All Its Cash by the End of This Year July 4, 2017
MabVax Therapeutics Board Of Directors Authorizes The Company To Explore Strategic Alternatives July 23, 2017
